{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:34:05Z","timestamp":1789842845674,"version":"4.0.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,17]]},"DOI":"10.7759\/cureus.75915","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T07:30:18Z","timestamp":1734507018000},"source":"Crossref","is-referenced-by-count":2,"title":["Apalutamide: A Cause of Neutropenic Sepsis"],"prefix":"10.7759","author":[{"given":"Urwah","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venga","family":"Vengadasalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2019.10.5.8","article-title":"Apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer","volume":"10","author":"Patel UJ","year":"2019","unstructured":"Patel UJ, Caulfield S. Apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. J Adv Pract Oncol. 2019, 10:501-7. 10.6004\/jadpro.2019.10.5.8","journal-title":"J Adv Pract Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith MR","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, et al.. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018, 378:1408-18. 10.1056\/NEJMoa1715546","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi KN","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, et al.. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019, 381:13-24. 10.1056\/NEJMoa1903307","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro MS","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, et al.. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011, 47:8-32. 10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.26502\/jcsct.5079204","article-title":"Apalutamide induced neutropenia: an unusual side effect and a literature review","volume":"7","author":"Moria FA","year":"2023","unstructured":"Moria FA, Park CL, Saleh RR. Apalutamide induced neutropenia: an unusual side effect and a literature review. J Cancer Sci Clin Ther. 2023, 7:135-40.","journal-title":"J Cancer Sci Clin Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00395-4","article-title":"Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"25","author":"Wenzel M","year":"2022","unstructured":"Wenzel M, Nocera L, Coll\u00e0 Ruvolo C, et al.. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Prostate Cancer Prostatic Dis. 2022, 25:139-48. 10.1038\/s41391-021-00395-4","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith MR","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, et al.. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022, 386:1132-42. 10.1056\/NEJMoa2119115","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis ID","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, et al.. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019, 381:121-31. 10.1056\/NEJMoa1903835","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi K","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, et al.. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design. Lancet. 2022, 399:1695-707. 10.1016\/S0140-6736(22)00367-1","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s1098-3597(06)80053-0","article-title":"Neutropenia: etiology and pathogenesis","volume":"8","author":"Schwartzberg LS","year":"2006","unstructured":"Schwartzberg LS. Neutropenia: etiology and pathogenesis. Clin Cornerstone. 2006, 8:5-11. 10.1016\/s1098-3597(06)80053-0","journal-title":"Clin Cornerstone"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/318093-apalutamide-a-cause-of-neutropenic-sepsis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T07:30:20Z","timestamp":1734507020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/318093-apalutamide-a-cause-of-neutropenic-sepsis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.75915","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,17]]}}}